Tuberculosis Week

Data on drug delivery discussed by researchers at Tokushima Bunri University

Tuberculosis Week Library Library Home This article was published in Tuberculosis Week, which you can subscribe to online.

"On the other hand, tuberculosis, caused by tubercle bacilli which possess the ability to survive in phagosome and grow in cell, poses a serious problem as an intractable disease because the efficacy of drug delivery to the target bacilli is low. We have developed a new approach to therapy against intracellular bacteria using a drug delivery system (DDS), to deliver an effective amount of drug to the target site, based on the phagocytotic ability of macrophages," wrote A. Yoshida and colleagues, Tokushima Bunri University.

The researchers concluded: "In this review, the development of an in vitro model of chronic infection by tubercle bacilli and therapy against tuberculosis using phagocytosis by macrophages and a DDS with microspheres are described."

Yoshida and colleagues published the results of their research in Anticancer Research (Development of a drug delivery system using a model that mimics chronic infection of Mycobacterium bovis Calmette-Guerin in alveolar macrophages. Anticancer Research, 2007;27(6A Sp. Iss):3707-3711).

For additional information, contact G.I. Soma, Tokushima Bunri University, Institute Health Science, Tokushima 7708514, Japan.

The publisher of the journal Anticancer Research can be contacted at: International Institute Anticancer Research, Editorial Office 1ST km Kapandritiou-Kalamou Rd. Kapandriti, PO Box 22, Athens 19014, Greece.

Keywords: Japan, Tokushima, Anticancer Therapy, Biotechnology, Cancer Research, Cutaneous Tuberculosis, Drug Delivery, Medical Device, Mycobacteria, Mycobacterium Tuberculosis, Phagocytosis, Therapy, Treatment, Tokushima Bunri University.

This article was prepared by Tuberculosis Week editors from staff and other reports. Copyright 2008, Tuberculosis Week via NewsRx.com.